AstraZeneca (AZN) reported first-quarter 2026 core earnings of $2.58 per share, slightly beating the Zacks Consensus Estimate of $2.57. Total revenues reached $15.29 billion, a 13% increase from the previous year, surpassing estimates of $14.96 billion.
Product sales accounted for $14.39 billion, up 7%, while alliance revenues increased 26% to $825 million. Key oncology drugs drove growth, with Tagrisso generating $1.83 billion, although it missed expectations of $1.86 billion. Imfinzi sales jumped 30% to $1.69 billion, while Lynparza’s revenues rose 2% to $781 million, exceeding estimates. AstraZeneca has reaffirmed its financial guidance for 2026, projecting mid-to-high single-digit revenue growth at constant exchange rates.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
